| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00535-016-1303-0 |
| P698 | PubMed publication ID | 28078469 |
| P50 | author | Seiichi Mawatari | Q88949828 |
| P2093 | author name string | Kohei Oda | |
| Tsutomu Tamai | |||
| Akihiro Moriuchi | |||
| Akio Ido | |||
| Hirofumi Uto | |||
| Takeshi Hori | |||
| Kazuaki Tabu | |||
| Kotaro Kumagai | |||
| Yukiko Inada | |||
| Yasunari Hiramine | |||
| Kunio Fujisaki | |||
| Haruka Sakae | |||
| Oki Taniyama | |||
| Akiko Saishoji | |||
| Dai Imanaka | |||
| Takeshi Kure | |||
| Masafumi Hashiguchi | |||
| Sho Ijuin | |||
| Akihiko Oshige | |||
| P2860 | cites work | All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study | Q42202767 |
| Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study | Q42210312 | ||
| Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial | Q42224933 | ||
| Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies | Q42231673 | ||
| Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection | Q42232746 | ||
| Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy | Q42978970 | ||
| Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection | Q42980276 | ||
| Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. | Q42996720 | ||
| Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors | Q43031629 | ||
| Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. | Q43039341 | ||
| Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan | Q43039581 | ||
| CD8+ T-cell interaction with HCV replicon cells: evidence for both cytokine- and cell-mediated antiviral activity. | Q43048298 | ||
| Viral Sequence Evolution in Acute Hepatitis C Virus Infection | Q27484985 | ||
| Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay | Q28548426 | ||
| IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy | Q29614896 | ||
| Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 | ||
| Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection | Q29620702 | ||
| Correlation between mutations in the interferon sensitivity-determining region of NS5A protein and viral load of hepatitis C virus subtypes 1b, 1c, and 2a | Q30757296 | ||
| Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection | Q33394468 | ||
| Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system | Q34022926 | ||
| A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors | Q34513827 | ||
| Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. | Q34638767 | ||
| Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection | Q35044909 | ||
| Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study | Q35055427 | ||
| Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis | Q35995534 | ||
| Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C | Q36371508 | ||
| Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines | Q36973392 | ||
| Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence | Q37349067 | ||
| Resistance to direct antiviral agents in patients with hepatitis C virus infection | Q37652739 | ||
| Changing trends in hepatitis C infection over the past 50 years in Japan | Q37672875 | ||
| Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. | Q37772959 | ||
| Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir | Q38391487 | ||
| Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. | Q38861177 | ||
| Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir | Q39687020 | ||
| Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism. | Q40791170 | ||
| Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. | Q41041935 | ||
| Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial | Q41343312 | ||
| Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials | Q42173527 | ||
| Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy | Q42175503 | ||
| P433 | issue | 7 | |
| P921 | main subject | daclatasvir | Q5207712 |
| P304 | page(s) | 855-867 | |
| P577 | publication date | 2017-01-11 | |
| P1433 | published in | Journal of Gastroenterology | Q15764399 |
| P1476 | title | New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir | |
| P478 | volume | 52 |
| Q64074565 | Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients |
| Q47657221 | Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia. |
| Q55212538 | The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir. |
| Q47560943 | The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort |
Search more.